Chimeric Therapeutics Ltd C.CHM

Primary Symbol: CHMMF

Healthcare Biotechnology

Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company. The Company is focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its pipeline includes CHM 1101 and CHM 2101. Its CHM 1101 (CLTX CAR-T) is a CAR-T therapy developed for the treatment of patients with solid tumors. CHM-1101 is being studied in a Phase 1B clinical trial in recurrent/ progressive glioblastoma. CHM 2101 is a third generation CDH17 CAR T, which is in preclinical development with a planned Phase I clinical trial in neuroendocrine tumors, colorectal, pancreatic and gastric cancer. Its pipeline also includes the CORE-NK platform, a clinically validated, off-the-shelf natural killer (NK) cell therapy platform to their portfolio (CHM 0201). The Company is also focused on the development of NK and CAR NK assets with plans for Phase 1B clinical trials in solid tumors and blood cancers.

OTCPK:CHMMF - Post by User

Chimeric Therapeutics Ltd > MONTHLY PROGRESS REPORT

<< Previous

Bullboard Posts

Next >>

Post by Predator2018on Jun 17, 2021 10:19am

456 Views

Post# 33401512

MONTHLY PROGRESS REPORT

As of May 31, 2021, the Company had debt obligations outstanding totaling $9,207,000 represented by 9,207 convertible debentures maturing March 29, 2022. The Company does not have the wherewithal at this time to repay the debentures when due. The debentures bear interest at 10% per annum payable semi-annually in December and June.

CHM_CSE_Form_7_-_May_2021_Monthly_Progress.pdf (thecse.com)

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals